Thrombopoietin and its receptor expression in pediatric patients with chronic immune thrombocytopenia
نویسندگان
چکیده
منابع مشابه
Successful Treatment with Thrombopoietin Receptor Agonist in Avoiding Splenectomy for Patients with Chronic Refractory Immune Thrombocytopenia
BACKGROUND Chronic immune thrombocytopenia (ITP) is a condition associated with significant morbidity; however the management options are often unsatisfactory with a portion of patients exhibiting a refractory-relapsing disease path despite various lines of treatment including splenectomy. As a thrombopoietin receptor agonist, eltrombopag (GlaxoSmithKline, Australia) provides a novel treatment ...
متن کاملWill thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
2015 Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count and increased bleeding tendency. Most children with ITP spontaneously recover. However, children with severe bleeding may require treatment. Traditional treatments such as corticosteroids or splenectomy are often associated with increased risks of infections. Currently, there is evidence that plat...
متن کاملEfficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis
Background and Aim Thrombopoietin receptor agonists (TPO-RAs) have been shown to be safe and effective for adults with chronic immune thrombocytopenia (ITP). The aim of this meta-analysis is to assess the efficacy and safety of thrombopoietin receptor agonists for children with chronic ITP. Materials and Methods Clinical randomized controlled trials (RCTs) evaluating the efficacy and safety o...
متن کاملthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia.
OBJECTIVE The development of myeloid malignancies is a concern when administering thrombopoietin receptor (or the myeloproliferative leukemia virus proto-oncogene product, MPL) agonists. Progression from myelodysplastic syndrome (MDS) to acute myelogenous leukemia [AML, 9 (6.12%) AML patients among 147 MDS subjects] was reported in a clinical trial. However, only one (0.15%) case of AML among 6...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hematology
سال: 2018
ISSN: 1607-8454
DOI: 10.1080/10245332.2017.1422316